New test could unlock Life-Extending drug for more women with ovarian cancer
NCT ID NCT04780945
Summary
This study aimed to see if a new laboratory test (called the RAD51 assay) could identify more women with recurrent ovarian cancer who would benefit from the drug olaparib. It focused on patients whose cancer had returned after initial treatment. The goal was to find a better way to match patients to this specific therapy than relying only on genetic tests for BRCA mutations.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOLOGOUS RECOMBINATION DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus Medical Center
Rotterdam, Netherlands
-
Leiden University Medical Center
Leiden, 2300RC, Netherlands
-
University Medical Center Groningen
Groningen, Netherlands
Conditions
Explore the condition pages connected to this study.